Sun Pharmaceutical Industries Limited has informed the Exchange regarding Change in Director(s) of the company.
SUNPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sun Pharma's board met on 22 May 2025 and approved audited standalone and consolidated results for Q4 and FY ended 31 March 2025, with the auditor issuing an unmodified (clean) opinion. The company recommended a final dividend of Rs. 5.50 per share, taking total FY25 dividend to Rs. 16 per share (including the Rs. 10.50 interim dividend declared earlier); record date is 7 July 2025 and payment by 8 August 2025. Standalone FY25 revenue from operations rose about 13% to Rs. 23,003 crore, while net profit jumped roughly 50% to Rs. 4,283 crore and EPS nearly doubled from Rs. 11.9 to Rs. 17.8. Ms. Vidhi Shanghvi was appointed Whole-time Director for 5 years (from 22 May 2025), subject to shareholder approval, while long-time non-executive director Mr. Sudhir Valia will retire and not seek reappointment at the upcoming AGM. M/s. KJB & CO LLP was also appointed as Secretarial Auditor for 5 years, and the 33rd AGM was scheduled for 31 July 2025.
Strong FY25 results with nearly 50% standalone profit growth and a clean audit are positive for shareholders, and the total Rs. 16 dividend signals healthy cash returns. The appointment of a Shanghvi family member (Vidhi Shanghvi) to the board continues promoter succession planning, while Sudhir Valia's retirement is a routine non-independent director exit and unlikely to materially affect operations.